Healthy Inc > Blog > Artemether Lumefantrine manufacturer India
Posted on:

How to take artemether lumefantrine Tablets?

In the pharmaceutical industry, Artemether 20 mg / Lumefantrine 120 mg (standard strength) is the “Gold Standard” for Artemisinin-based Combination Therapy (ACT). As a pharmacist and manufacturer, I view the administration of this drug as a high-precision process—therapeutic failure is rarely due to the drug itself, but rather to incorrect timing or dietary choices.

At your WHO-GMP facility in Mumbai, ensuring your B2B clients receive clear “Patient Instruction Guides” is vital for maintaining the clinical reputation of your antimalarial brand.

The “Standard 6-Dose” Regimen

For uncomplicated Plasmodium falciparum malaria, the treatment is typically spread over three days to ensure the entire life cycle of the parasite is intercepted.

Dose NumberTiming of Administration
Dose 1Immediately upon diagnosis.
Dose 2Exactly 8 hours after the first dose.
Dose 324 hours after the first dose (Day 2).
Dose 4Exactly 12 hours after Dose 3.
Dose 548 hours after the first dose (Day 3).
Dose 6Exactly 12 hours after Dose 5.

Mechanism: The “Fat-Dependent” Absorption

The most critical technical aspect of taking this medication is its interaction with lipids.

The Lumefantrine Factor: While Artemether is absorbed relatively easily, Lumefantrine is highly lipophilic (fat-loving).

The Dietary Requirement: It must be taken with a meal rich in fat (e.g., whole milk, eggs, or gravy). Taking it on an empty stomach can reduce Lumefantrine absorption by up to 16 times, leading to treatment failure and potential drug resistance.

The “Vomiting” Protocol: If a patient vomits within 1 hour of taking a dose, they must retake the full dose immediately.

The Pharmacist’s “Technical Warning”

  • Grapefruit Juice Contraindication: Patients must avoid grapefruit juice, as it inhibits the CYP3A4 enzyme, which can lead to dangerously high levels of the drug in the bloodstream.

  • Cardiac Precaution: This combination can cause a slight prolongation of the QT interval. Advise patients to report any palpitations or dizziness immediately.

  • Complete the Course: Even if the patient feels better after 24 hours (which is common due to the rapid action of Artemether), they must finish all 6 doses to prevent the malaria from returning.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Pediatric Dispersible” USP: On your marketplace, highlight your Dispersible Tablets for children. These are designed to dissolve in a small amount of water, making them easier to administer to infants than crushing adult tablets.

  • Stability for Export: Artemether is heat-labile. Utilizing Alu-Alu (Cold-form) blister packaging is the non-negotiable industry standard to maintain a 36-month shelf life in Zone IVb tropical regions.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers to support your firm’s registration in international NGO and government health tenders (e.g., Global Fund/USAID).

Artemether & Lumefantrine Tablets

 

Posted on:

What is the brand name for artemether and lumefantrine tablets?

In the pharmaceutical industry, the combination of Artemether and Lumefantrine is the global “gold standard” for Artemisinin-based Combination Therapy (ACT). As a pharmacist and manufacturer, I view this combination as the most critical asset for any firm exporting to malaria-endemic regions.

While the innovator brand is globally recognized, the Indian pharmaceutical sector provides the majority of the world’s high-quality generic versions for the public and private sectors.

Primary Brand Names

CategoryBrand NamesManufacturer
Global InnovatorCoartem, RiametNovartis
Leading Indian BrandsLumet, Lumerax, Combither, Falcinil-LFCipla, Ipca, Aristo, Zuventus
Common Generic Export BrandsArtefan, Lumart, Arh L, Falcynate-LFAjanta Pharma, Lincoln Pharma, various

Formulations & Strengths

At your WHO-GMP facility in Mumbai, you likely deal with three primary strengths, which are essential for correct weight-based dosing in pediatric and adult populations:

Standard Strength (20/120): 20 mg Artemether + 120 mg Lumefantrine (Yellow, round, scored tablets).

Forte Strength (80/480): 80 mg Artemether + 480 mg Lumefantrine (High-strength to reduce pill burden for adults).

Dispersible Tablets: Specifically designed for infants and children; these dissolve rapidly in a small amount of water or milk.

The Pharmacist’s “Technical Warning”

  • The “Fatty Meal” Rule: Lumefantrine is highly lipophilic. Patients must take the tablets with food or a drink rich in fat (like milk). Taking it on an empty stomach can reduce absorption by up to 90%, potentially leading to treatment failure.

  • QT Prolongation Risk: As we discussed, this combination can prolong the QT interval. It must be avoided with other QT-prolonging drugs like Levofloxacin, Amiodarone, or Halofantrine.

  • The 1-Hour Vomit Rule: If a patient vomits within one hour of taking the dose, they must repeat the full dose immediately to ensure therapeutic levels are reached.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility:

  • The “Infant Design” Trend: In 2025–2026, regulators (like Swissmedic) have approved specialized cherry-flavored dispersible versions for infants under 4.5 kg. Developing these can give your marketplace a unique technical edge.

  • Stability for Export: Artemether is sensitive to heat. Utilizing Alu-Alu blister packaging is mandatory to ensure a 36-month shelf life in tropical Zone IVb regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international tenders (UNICEF, Global Fund), which prioritize WHO-prequalified manufacturers.

Artemether & Lumefantrine Tablets

Posted on:

Is coartem safe in pregnancy?

In the pharmaceutical industry, Coartem (the fixed-dose combination of Artemether and Lumefantrine) is the gold standard for Artemisinin-based Combination Therapy (ACT). As a pharmacist and manufacturer, I view its safety in pregnancy as a carefully tiered clinical decision based on the trimester and the severity of the malaria.

At your WHO-GMP facility in Mumbai, this SKU is a high-priority export item for African and Southeast Asian markets. Following the updated 2026 WHO guidelines, the “safety” of Coartem has expanded, particularly in the later stages of pregnancy.

Clinical Safety by Trimester

The safety profile of Coartem changes as the pregnancy progresses:

  • First Trimester: Historically, Coartem was avoided in the first 13 weeks due to limited data. However, recent large-scale studies show no increased risk of miscarriage or birth defects. The current WHO recommendation is that ACTs (including Coartem) should be used if it is the only effective treatment available, as the risk of malaria to the mother and fetus is far greater than the risk of the drug.

  • Second & Third Trimesters: Coartem is considered safe and is the first-line treatment for uncomplicated P. falciparum malaria. It has a proven track record of clearing parasites quickly without harming the developing fetus.

    Lactation: It is generally considered safe during breastfeeding, as the amount of drug excreted in breast milk is negligible.

Mechanism: Dual-Action Parasite Clearance

Coartem uses two distinct mechanisms to ensure the malaria parasite is completely eradicated while protecting maternal health.

Artemether (The Rapid Responder): This derivative works by creating reactive free radicals that damage the parasite’s proteins and membranes. It provides a rapid “knockdown” effect, reducing the parasite load within hours.

Lumefantrine (The Long-Term Guard): This component has a much longer half-life. It remains in the blood to clear any remaining parasites and prevents the “recrudescence” (return) of the infection.

The Pharmacist’s “Technical Warning”

  • The “Fatty Meal” Requirement: For maximum efficacy, Coartem must be taken with food, preferably a meal containing fat (like milk or eggs). Fat increases the absorption of Lumefantrine by up to 16 times. Without fat, the treatment may fail.

  • Cardiac Monitoring: Both components can slightly prolong the QT interval. Use with caution if the pregnant patient is taking other medications that affect heart rhythm (like certain antibiotics or anti-nausea drugs).

  • Severe vs. Uncomplicated: Coartem is for uncomplicated malaria only. If a pregnant woman has cerebral malaria or persistent vomiting, she requires IV Artesunate.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “ACT-Plus” Branding: On your marketplace, emphasize that your Coartem follows the WHO-Prequalification standards. This is the primary requirement for UN and Global Fund tenders.

  • Stability for Export: Artemether is highly sensitive to heat and moisture. To ensure a 36-month shelf life in Zone IVb tropical regions, you must use Alu-Alu (Cold-form) blister packaging.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international infectious disease and maternal health tenders.

Artemether & Lumefantrine Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

FactorClinical DataSafety Impact
Transfer to MilkVery Low: Only minute amounts are excreted into breast milk due to its rapid metabolism.The amount the infant receives is far below a therapeutic dose.
Infant AbsorptionLimited: Artemether has low oral bioavailability in infants when consumed via milk.Minimal risk of systemic toxicity in the nursing baby.
Infant Side EffectsNone Reported: No adverse events have been documented in infants whose mothers were treated with ACTs.High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

FactorClinical DataSafety Impact
Transfer to MilkVery Low: Only minute amounts are excreted into breast milk due to its rapid metabolism.The amount the infant receives is far below a therapeutic dose.
Infant AbsorptionLimited: Artemether has low oral bioavailability in infants when consumed via milk.Minimal risk of systemic toxicity in the nursing baby.
Infant Side EffectsNone Reported: No adverse events have been documented in infants whose mothers were treated with ACTs.High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

FactorClinical DataSafety Impact
Transfer to MilkVery Low: Only minute amounts are excreted into breast milk due to its rapid metabolism.The amount the infant receives is far below a therapeutic dose.
Infant AbsorptionLimited: Artemether has low oral bioavailability in infants when consumed via milk.Minimal risk of systemic toxicity in the nursing baby.
Infant Side EffectsNone Reported: No adverse events have been documented in infants whose mothers were treated with ACTs.High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

 

Add to cart